Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Schizophrenia

Free Subscription Articles published in J Clin Psychiatry Retrieve available abstracts of 54 articles: HTML format

Single Articles

July 2026
1. CITROME L, Farovik A, Palma AM, Yildirim M, et al
   Effects of Brexpiprazole on Functioning in Patients With Schizophrenia Who Have Hostility and Agitation Symptoms: Post Hoc Analysis of Short- and Long-Term Trials.
   J Clin Psychiatry. 2026;87:26m16448.
   PubMed     Abstract available
   
   
   
2. NAGAMINE T
   GLP-1 Receptor Agonists for Non-obese Asian Patients With Schizophrenia: Beyond the Body Mass Index Paradigm.
   J Clin Psychiatry. 2026;87:26lr16549.
   PubMed    
   
   
   June 2026
3. STEINLE JT, Shankar S, Siegel JS, Cabassa LJ, et al
   Hallucinogen-Psychosis Associations Are Confounded by Baseline Psychiatric History.
   J Clin Psychiatry. 2026;87:25m16034.
   PubMed     Abstract available
   
   
   May 2026
4. CITROME L, Bell Lynum KS, Zhang Z, Atkins N Jr, et al
   Aripiprazole Once-Monthly for Patients Diagnosed With Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed.
   J Clin Psychiatry. 2026;87:26m16359.
   PubMed     Abstract available
   
   
   
5. KUMAR N, Prasad S, Srivastava MVP, Kalaivani M, et al
   Effects of Experimental Intermittent Theta Burst Stimulation on Negative Symptoms of Schizophrenia: A Double-Blind Sham-Controlled Study.
   J Clin Psychiatry. 2026;87:25m16093.
   PubMed     Abstract available
   
   
   April 2026
6. UMBRICHT D, Abt M, Derks M, Hernandez MC, et al
   A Phase 2b Multicenter Study to Evaluate Basmisanil as an Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia.
   J Clin Psychiatry. 2026;87:25m16022.
   PubMed     Abstract available
   
   
   March 2026
7. SCANLON F, Mueser KT, Cather C
   Correlates and Predictors of Criminal Legal Involvement in People With First-Episode Psychosis.
   J Clin Psychiatry. 2026;87:25m15991.
   PubMed     Abstract available
   
   
   
8. 
   Correction. The Efficacy of Olanzapine/Samidorphan on Negative Symptoms: A Post Hoc Analysis of 56-Week Treatment in Patients With Schizophrenia.
   J Clin Psychiatry. 2026;87:26lcx16443.
   PubMed    
   
   
   
9. RAMIREZ J, Correll CU
   Life After Clozapine: Managing Treatment-Resistant Schizophrenia When Clozapine Is No Longer an Option.
   J Clin Psychiatry. 2026;87:26ac16364.
   PubMed    
   
   
   
10. MCINTYRE RS, Matthews DM, Arevalo C, McDonnell D, et al
    The Efficacy of Olanzapine/Samidorphan on Negative Symptoms: A Post Hoc Analysis of 56-Week Treatment in Patients With Schizophrenia.
    J Clin Psychiatry. 2026;87:25m16170.
    PubMed     Abstract available
    
    
    February 2026
11. JOO SW, Lee J
    Latency to Long-Acting Injectable Antipsychotic Initiation and Psychiatric Hospitalization in First-Episode Schizophrenia.
    J Clin Psychiatry. 2026;87:25m16048.
    PubMed     Abstract available
    
    
    January 2026
12. ANDRADE C
    The Position of Clozapine in Patients With Treatment-Resistant Schizophrenia: Reply to Mattes.
    J Clin Psychiatry. 2026;87:25lr16256a.
    PubMed    
    
    
    
13. DAMME KSF, Mittal VA
    Exercise Reduces Dysphoria in Clinical High Risk for Psychosis: A Randomized Controlled Trial.
    J Clin Psychiatry. 2026;87:25br16079.
    PubMed    
    
    
    December 2025
14. TANDON R, Barch DM, Buchanan RW, Green MF, et al
    Psychosocial Interventions and Functional Recovery in Schizophrenia-Realizing Opportunities Today.
    J Clin Psychiatry. 2025;86:hfrecachi2505.
    PubMed     Abstract available
    
    
    November 2025
15. MELNICK I, Crown EC, Zinzuvadia M, Halassa MM, et al
    Real-World Implementation of Xanomeline-Trospium in Schizophrenia: A Consensus Panel Report.
    J Clin Psychiatry. 2025;86:hxtachi2509.
    PubMed     Abstract available
    
    
    October 2025
16. FAN X, Freudenreich O, Jarskog LF, McEvoy J, et al
    Brexpiprazole for the Treatment of Co-occurring Schizophrenia and Substance Use Disorder: A Multisite, Randomized, Controlled Trial.
    J Clin Psychiatry. 2025;86:25m15786.
    PubMed     Abstract available
    
    
    August 2025
17. ANDRADE C
    The Superiority of Clozapine Over Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: Room for Doubt.
    J Clin Psychiatry. 2025;86:25f16038.
    PubMed     Abstract available
    
    
    
18. CORRELL CU, Achtyes ED, Sajatovic M, Saklad SR, et al
    Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Schizophrenia: A Consensus Panel Report.
    J Clin Psychiatry. 2025;86:plunlai2424ah2.
    PubMed     Abstract available
    
    
    
19. CHOI BM, Singh T, Nili M, Lam C, et al
    Understanding the Characteristics and Burden of Cognitive Impairments in Schizophrenia in the US: Medical Expenditure Panel Survey.
    J Clin Psychiatry. 2025;86:25m15794.
    PubMed     Abstract available
    
    
    July 2025
20. ZHANG T, Xu L, Wei Y, Tang X, et al
    Efficiency and Extent of Niacin-Induced Skin Flushing Patterns in Early Stages of Psychosis.
    J Clin Psychiatry. 2025;86:24m15559.
    PubMed     Abstract available
    
    
    
21. BALLESTEROS A, Flores-Lopez M, Sanchez-Torres AM, Gil-Berrozpe GJ, et al
    Exploring Vascular Endothelial Growth Factor and Other Blood-Brain Barrier Biomarkers in Cognition of First-Episode Psychosis: An Observational Study.
    J Clin Psychiatry. 2025;86:24m15486.
    PubMed     Abstract available
    
    
    June 2025
22. ANDRADE C
    Schizophrenia, Antipsychotic Drugs, and Risk of Breast Cancer.
    J Clin Psychiatry. 2025;86:25f15960.
    PubMed     Abstract available
    
    
    
23. GOLDBERG JF, Achtyes ED, Correll CU, Sajatovic M, et al
    Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report.
    J Clin Psychiatry. 2025;86:plunlai2424ah1.
    PubMed     Abstract available
    
    
    
24. RICCIARDI FL, Melnitsky JL, Peleg SB, Govil P, et al
    Worth the Weight? The Challenges of Administering the Glucagon-Like Peptide 1 Receptor Agonist Semaglutide With Long-Term Olanzapine Use in a Patient With Schizophrenia.
    J Clin Psychiatry. 2025;86:25cr15857.
    PubMed    
    
    
    March 2025
25. TSAI SJ, Cheng CM, Chang WH, Bai YM, et al
    Effects of Parental Severe Mental Disorders on All-Cause and Suicide Mortalities in Adolescents and Young Adults With Major Depressive Disorder.
    J Clin Psychiatry. 2025;86:24m15476.
    PubMed     Abstract available
    
    
    
26. YEUNG PP, Breier A, Zhu H, Kaul I, et al
    Xanomeline and Trospium Chloride for the Treatment of Agitation Associated With Schizophrenia: PANSS-Excited Component Results From 3 Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials.
    J Clin Psychiatry. 2025;86:24m15668.
    PubMed     Abstract available
    
    
    February 2025
27. KAUL I, Claxton A, Sawchak S, Sauder C, et al
    Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the 5-Week, Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials.
    J Clin Psychiatry. 2025;86:24m15497.
    PubMed     Abstract available
    
    
    
28. CITROME L
    Understanding the Tolerability Profile of Xanomeline-Trospium Combination for the Treatment of Schizophrenia.
    J Clin Psychiatry. 2025;86:25com15775.
    PubMed    
    
    
    January 2025
29. RAMIREZ J, Correll CU
    Relationship Between Trauma, PTSD, and Schizophrenia: Relevance for Outcomes, Screening, and Interventions.
    J Clin Psychiatry. 2025;86:24ac15773.
    PubMed    
    
    
    
30. DIALLO-MONTFORD K, Schwind JS, Smallwood SW, Qotineh A, et al
    Psychological Challenges of Adults With Severe Mental Illness During the COVID-19 Pandemic.
    J Clin Psychiatry. 2025;86:24m15448.
    PubMed     Abstract available
    
    
    
31. HUANG J, Chen A, Jin H, Liu F, et al
    Efficacy and Safety of Sulforaphane Added to Antipsychotics for the Treatment of Negative Symptoms of Schizophrenia: A Randomized Controlled Trial.
    J Clin Psychiatry. 2025;86:24m15272.
    PubMed     Abstract available
    
    
    
32. CORRELL CU, Doane MJ, McDonnell D, Akerman S, et al
    Olanzapine/Samidorphan Effects on Weight Gain: An Individual Patient Data Meta-Analysis of Phase 2 and 3 Randomized Double-Blind Studies.
    J Clin Psychiatry. 2025;86:24m15526.
    PubMed     Abstract available
    
    
    December 2024
33. BALLON JS, Kahn RS, Arevalo C, Dunbar M, et al
    Long-Term Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: Results of a 4-Year Open-Label Study.
    J Clin Psychiatry. 2024;86:24m15511.
    PubMed     Abstract available
    
    
    November 2024
34. JAIN R, Chepke C, Davis LL, McIntyre RS, et al
    Dysregulation of Noradrenergic Activity: Its Role in Conceptualizing and Treating Major Depressive Disorder, Schizophrenia, Agitation in Alzheimer's Disease, and Posttraumatic Stress Disorder.
    J Clin Psychiatry. 2024;85:plunaro2417ah.
    PubMed     Abstract available
    
    
    September 2024
35. DE WINTER L, Jelsma A, Vermeulen JM, van Tricht M, et al
    Long-Term Changes in Cognition Among Patients With Schizophrenia Spectrum Disorders and Different Durations of Illness: A Meta-Analysis.
    J Clin Psychiatry. 2024;85:23r15134.
    PubMed     Abstract available
    
    
    August 2024
36. CORRELL CU, Xiang P, Sarikonda K, Bhagvandas N, et al
    The Economic Impact of Cognitive Impairment and Negative Symptoms in Schizophrenia: A Targeted Literature Review With a Focus on Outcomes Relevant to Health Care Decision-Makers in the United States.
    J Clin Psychiatry. 2024;85:24r15316.
    PubMed     Abstract available
    
    
    
37. KINON BJ, Leucht S, Tamminga C, Breier A, et al
    Rationale for Adjunctive Treatment Targeting Multiple Mechanisms in Schizophrenia.
    J Clin Psychiatry. 2024;85:23nr15240.
    PubMed     Abstract available
    
    
    
38. SOMMI RW, Saklad SR, Weiden PJ, Still D, et al
    Initiating Aripiprazole Lauroxil: Post Hoc Analysis of Safety and Tolerability of 1-Day and 21-Day Regimens.
    J Clin Psychiatry. 2024;85:23m15132.
    PubMed     Abstract available
    
    
    June 2024
39. VACCARINO SR, Vaccarino AL
    Cognitive Effects of Electroconvulsive Therapy in Schizophrenia: A Systematic Review.
    J Clin Psychiatry. 2024;85:23r15045.
    PubMed     Abstract available
    
    
    May 2024
40. KOBYLSKI LA, Le HN, Freeman MP, Cohen LS, et al
    Enhancing Postpartum Psychosis Care With Qualitative Research: Current Findings and Future Directions.
    J Clin Psychiatry. 2024;85:24com15305.
    PubMed    
    
    
    
41. NASRALLAH HA
    Psychosis, Inflammatory Biomarkers, and Subtypes of Childhood Trauma.
    J Clin Psychiatry. 2024;85:24com15310.
    PubMed    
    
    
    
42. CUNAT O, Arranz B, Vila-Badia R, Serra-Arumi C, et al
    Relationship Between Exposure to Emotional Neglect and the Inflammatory Biomarkers Neutrophil-to-Lymphocyte, Monocyte-to-Lymphocyte, and Platelet-to-Lymphocyte Ratios in Patients With First-Episode Psychosis.
    J Clin Psychiatry. 2024;85:23m15141.
    PubMed     Abstract available
    
    
    
43. BRAINERD DR, Alexander B, Tague MJ, Lund BC, et al
    Association Between Clozapine Exposure and Risk of Hematologic Malignancies in Veterans With Schizophrenia.
    J Clin Psychiatry. 2024;85:23m15149.
    PubMed     Abstract available
    
    
    
44. ANDRADE C
    Antipsychotic Medication Continuation vs Taper and Discontinuation in Patients With Schizophrenia and Other Nonaffective Psychotic Disorders.
    J Clin Psychiatry. 2024;85:24f15363.
    PubMed     Abstract available
    
    
    
45. TIEN Y, Wang XY, Huang SC, Huang HP, et al
    Beneficial Effects of Concomitant Long-Acting Injectable Antipsychotics on Time to Rehospitalization in Patients With Treatment-Resistant Schizophrenia Receiving Clozapine: A Retrospective Cohort Study.
    J Clin Psychiatry. 2024;85:23m15071.
    PubMed     Abstract available
    
    
    April 2024
46. SIMON GE, Rossom RC, Iturralde E, Ahmedani BK, et al
    Clozapine Use Among People With Psychotic Disorders Who Experience Specific Indications for Clozapine.
    J Clin Psychiatry. 2024;85:23m14833.
    PubMed     Abstract available
    
    
    February 2024
47. CITROME L, Yagoda S, Bidollari I, Wang M, et al
    Safety and Tolerability of Starting Aripiprazole Lauroxil With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months Using Paliperidone Palmitate Monthly as an Active Control in Patients With Schizophre
    J Clin Psychiatry. 2024;85:23m15095.
    PubMed     Abstract available
    
    
    January 2024
48. MIURA I, Sano F, Sakaguchi R, Okamoto K, et al
    Effect of Lurasidone on Social Functioning in Schizophrenia: Post Hoc Analysis of the JEWEL Study.
    J Clin Psychiatry. 2024;85:23m14881.
    PubMed     Abstract available
    
    
    
49. ITURRALDE E, Fazzolari L, Slama NE, Alexeeff SE, et al
    Telehealth Collaborative Care Led by Clinical Pharmacists for People With Psychosis or Bipolar Disorder: A Propensity Weighted Comparison With Usual Psychiatric Care.
    J Clin Psychiatry. 2024;85:23m14917.
    PubMed     Abstract available
    
    
    November 2023
50. LONDON SM, Cawkwell PB, Shinn AK
    Medication Adherence in a Transdiagnostic First-Episode Psychosis Sample.
    J Clin Psychiatry. 2023;84:23m14947.
    PubMed     Abstract available
    
    
    October 2023
51. VERGARA L, de la Serna E, Sugranyes G, Puig O, et al
    Obsessive-Compulsive Spectrum Symptoms Are Associated With Functional Impairment in Children and Adolescents With Psychosis Risk Syndrome: The CAPRIS Study.
    J Clin Psychiatry. 2023;84:22m14698.
    PubMed     Abstract available
    
    
    September 2023
52. LOPENA OJ, Alphs LD, Sajatovic M, Turkoz I, et al
    Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia: An Integrated Patient-Level Post Hoc Analysis.
    J Clin Psychiatry. 2023;84:23m14788.
    PubMed     Abstract available
    
    
    
53. CHENG CM, Chang WH, Tsai SJ, Li CT, et al
    Risk of All-Cause and Suicide Death in Patients With Schizophrenia: An Entire-Population Longitudinal Study in Taiwan.
    J Clin Psychiatry. 2023;84:22m14747.
    PubMed     Abstract available
    
    
    
54. CITROME L, Such P, Yildirim M, Madera-McDonough J, et al
    Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg: Secondary Analysis of Outcomes in Adult Patients With Schizophrenia in a Randomized, Open-label, Parallel-Arm, Pivotal Study.
    J Clin Psychiatry. 2023;84:23m14873.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum